we’re eargo. a company made up of ent surgeons, tech geeks and dreamers, united in our belief that people should be able to hear life to the fullest. because the world is full of great things to hear. and because, well, we really like people. it's because we like people that we do what we do. we want the best for them, and this is our way to make sure they get it (we also like pina coladas, cuddly puppies and long walks on the beach, in case you’re wondering). we don't believe that caring for your hearing health should come at the cost of compromising your lifestyle or appearance. that's why we’ve created devices that work superbly, are easy to use and – because of our patented flexi fibers – are incredibly comfortable and essentially invisible. we start with the user, the person who's going to open the eargo box with eager anticipation, and build all of our products and experiences in ways that make them feel understood and cared for. that pays off their eager anticipation. we feel th
Company profile
Ticker
EAR
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
SEC CIK
Corporate docs
Subsidiaries
Eargo Hearing, Inc. • Eargo Screening, LLC ...
IRS number
273879804
EAR stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
26 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Feb 24
RW
Registration withdrawal request
16 Feb 24
SC 13E3/A
Going private transaction (amended)
16 Feb 24
25-NSE
Exchange delisting
16 Feb 24
8-K
Eargo Announces Closing of Acquisition By Patient Square Capital
16 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
14 Feb 24
DEFA14A
Additional proxy soliciting materials
7 Feb 24
Transcripts
EAR
Earnings call transcript
2023 Q1
11 May 23
EAR
Earnings call transcript
2022 Q4
23 Mar 23
EAR
Earnings call transcript
2022 Q3
6 Nov 22
EAR
Earnings call transcript
2022 Q2
9 Aug 22
EAR
Earnings call transcript
2021 Q2
13 Aug 21
EAR
Earnings call transcript
2021 Q1
13 May 21
EAR
Earnings call transcript
2020 Q4
26 Feb 21
EAR
Earnings call transcript
2020 Q3
19 Nov 20
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 46.02 mm | 46.02 mm | 46.02 mm | 46.02 mm | 46.02 mm | 46.02 mm |
Cash burn (monthly) | 4.92 mm | 3.50 mm | 5.98 mm | 9.18 mm | 4.91 mm | 6.28 mm |
Cash used (since last report) | 32.70 mm | 23.30 mm | 39.77 mm | 61.06 mm | 32.66 mm | 41.75 mm |
Cash remaining | 13.32 mm | 22.73 mm | 6.25 mm | -15.04 mm | 13.37 mm | 4.27 mm |
Runway (months of cash) | 2.7 | 6.5 | 1.0 | -1.6 | 2.7 | 0.7 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 22 |
Opened positions | 3 |
Closed positions | 7 |
Increased positions | 4 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 82.38 bn |
Total shares | 343.40 mm |
Total puts | 1.88 k |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
PSC Echo | 316.43 mm | $0.00 |
Patient Square Capital | 15.82 mm | $78.00 bn |
New Enterprise Associates 15 | 4.52 mm | $150.07 mm |
Alger Associates | 1.96 mm | $39.15 mm |
Longitude Capital Partners IV | 1.92 mm | $64.33 mm |
Gilde Healthcare Holding B.V. | 1.87 mm | $1.30 mm |
BLK Blackrock | 242.88 k | $1.20 bn |
NEA Management | 207.89 k | $1.02 bn |
Nan Fung | 147.90 k | $729.17 mm |
Vanguard | 85.29 k | $420.48 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Feb 24 | Spence Donald J | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 0 | 5,000 | 0.00 | 0 |
16 Feb 24 | Spence Donald J | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 0 | 5,859 | 0.00 | 0 |
16 Feb 24 | Katie J Bayne | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 0 | 5,000 | 0.00 | 0 |
16 Feb 24 | Katie J Bayne | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,703 | 0.00 | 0 |
16 Feb 24 | Katie J Bayne | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,740 | 0.00 | 0 |
16 Feb 24 | Katie J Bayne | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 0 | 516 | 0.00 | 0 |
16 Feb 24 | David James Wu | Common Stock | Sale back to company | Dispose D | No | No | 0 | 25,463 | 0.00 | 0 |
16 Feb 24 | David James Wu | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 0 | 5,000 | 0.00 | 0 |
16 Feb 24 | David James Wu | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,703 | 0.00 | 0 |
16 Feb 24 | David James Wu | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,740 | 0.00 | 0 |